The global Congenital Hyperinsulinism Treatment Market deals with a rare genetic disorder that causes episodes of low blood sugar (hypoglycemia) in infants and children. The condition can lead to seizures, developmental delays and other health complications if not treated properly. The treatment products in this market include medications like diazoxide and somatostatin analogs and surgical interventions like partial pancreatectomy to manage insulin production.
The global Congenital Hyperinsulinism Treatment Market is estimated to be valued at US$ 217.74 Mn in 2023 and is expected to exhibit a CAGR of 5.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The key trend propelling the congenital hyperinsulinism treatment market is the increasing adoption of surgical interventions like partial pancreatectomy for treating resistant cases. Around 30-40% of congenital hyperinsulinism cases do not respond adequately to medical management alone and require surgery. Surgical resection of a part of the pancreas helps reduce insulin production and control hypoglycemia. With advances in surgical techniques, partial pancreatectomy has become a relatively safe procedure with high cure rates for congenital hyperinsulinism. This has contributed to the growth of the congenital hyperinsulinism treatment market.
SWOT Analysis
Strength: The congenital hyperinsulinism treatment market is driven by the rising prevalence of congenital hyperinsulinism and increasing availability of treatment options.
Weakness: Limited availability and high cost of treatment options may hinder the market growth.
Opportunity: Growing research and development activities to develop new treatment options provide lucrative opportunities in the market.
Threats: Stringent regulations for product approvals and reimbursement challenges pose major threats to the market.
Key Takeaways
The Global Congenital Hyperinsulinism Treatment Market Size is expected to witness high growth. Regional analysis The North America region currently dominates the congenital hyperinsulinism treatment market due to growing awareness regarding congenital hyperinsulinism and increasing healthcare expenditure. The Asia Pacific region is expected to witness the fastest growth during the forecast period owing to rising healthcare spending and developing healthcare facilities in emerging economies such as China and India.
Key players operating in the congenital hyperinsulinism treatment market are Zealand Pharma A/S, Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Rezolute, Inc., Hanmi Pharm.Co., Ltd., Fresenius Kabi AG, Eiger BioPharmaceuticals.,Crinetics Pharmaceuticals, Inc., AmideBio,LLC, Jolly Healthcare, e5 Pharma,LLC, Merck & Co.,Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals,Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd.The key players are focusing on new product approvals and launches to strengthen their market position. For instance, in April 2022, Zealand Pharma A/S received FDA approval for its drug Zegalogue (dasiglucagon) for the treatment of congenital hyperinsulinism.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.